Juzen-taiho-to (JTT) is an immunostimulatory herbal formulation that is clinically used in East Asia for cancer patients undergoing chemotherapy and radiation. The formulation stimulates various leukocytes, including T, B, and NK cells and macrophages (MΦ). Although JTT is known to contain numerous compounds with various pharmacological activities, it is not clear which compounds are responsible for the stimulation of individual cell types. Here, we conducted what we call, “biomarker-guided screening,” to purify compounds responsible for the MΦ stimulatory activity. To this end, gene expression was analyzed by a DNA array for MΦ treated with JTT and DMSO (vehicle control), which identified intercellular adhesion molecule 1 (ICAM-1) as a biomarker of MΦ-stimulation by JTT. A qRT-PCR assay of ICAM-1 was then used to guide the purification of active compounds. The screening resulted in the purification of a glycolipid mixture, containing β-glucosylceramides. The glycolipid mixture potently stimulated ICAM-1 expression in primary dendritic cells (DC) as well as in primary CD14+ (MΦ) cells. Identification of this glycolipid mixture opens an opportunity for further studies to understand how plant-derived glycolipids stimulate MΦ and DC in a safe and effective manner as demonstrated by JTT.